TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2864943

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atracurium and Vecuronium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vecuronium and Pancuronium
Number of subjects: 0
Study: 31145003

Group type: EXPERIMENTAL
Intervention: Behavioral group support intervention
Number of subjects: 16
Study: 29264780

Group type: EXPERIMENTAL
Intervention: LRYGB
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: LSG
Number of subjects: 33
Study: 26592200

Group type: EXPERIMENTAL
Intervention: Withdrawal from carbamazepine (CBZ)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Non-withdrawal from carbamazepine (CBZ)
Number of subjects: 160
Study: 24645671

Group type: EXPERIMENTAL
Intervention: Nutrient-enriched formula
Number of subjects: 207

Group type: COMPARATOR
Intervention: Standard full-term formula
Number of subjects: 207
Study: 23342412

Group type: EXPERIMENTAL
Intervention: Glycated albumin (GA) measurements
Number of subjects: 1211

Group type: COMPARATOR
Intervention: Fasting plasma glucose (FPG)
Number of subjects: 1211

Group type: COMPARATOR
Intervention: Haemoglobin A1c (HbA1c)
Number of subjects: 1211
Study: 20415689

Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 50 (BIAsp 50)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 70 (BIAsp 70)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Both BIAsp 50 and BIAsp 70
Number of subjects: 75
Study: 19066382

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.05 mg/kg
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.15 mg/kg
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.5 mg/kg
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 215
Study: 16029524

Group type: EXPERIMENTAL
Intervention: Early invasive treatment
Number of subjects: 545

Group type: COMPARATOR
Intervention: Early conservative treatment
Number of subjects: 545
Study: 13129479

Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acid (MUFA)‐rich diet
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saturated fatty acid (SFA)‐rich diet
Number of subjects: 8
Study: 10647168

Group type: EXPERIMENTAL
Intervention: Immobilization
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Mobilization
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Specific exercise
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Traction
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Physical therapy treatment based on classification
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Interrater reliability of classification system
Number of subjects: 120
Study: 8672379

Group type: EXPERIMENTAL
Intervention: Transdermal hyoscine
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 1341133

Group type: EXPERIMENTAL
Intervention: 4 ml of a mixture including 3 ml of 0.5% bupivacaine, 1 ml fentanyl in 1 ml of 10% dextrose solution (Group II)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: 4 ml of a mixture including 3 ml of 0.5% bupivacaine, 0.15 mg clonidine (Group IV)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: 4 ml of 0.5% bupivacaine at 5 degrees C (Group VI)
Number of subjects: 152

Group type: COMPARATOR
Intervention: 4 ml of 0.5% bupivacaine at 27 degrees C (Group I)
Number of subjects: 152

Group type: COMPARATOR
Intervention: 4 ml of 0.5% bupivacaine at 20 degrees C (Group V)
Number of subjects: 152

Group type: COMPARATOR
Intervention: 4 ml of a mixture including 3 ml of 0.5% bupivacaine, 0.20 mg adrenaline (Group III)
Number of subjects: 152
Study: 4044828

Group type: EXPERIMENTAL
Intervention: Lean men at rest after a 750-kcal mixed meal
Number of subjects: 16

Group type: COMPARATOR
Intervention: Obese men at rest after a 750-kcal mixed meal
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Lean men post exercise
Number of subjects: 16

Group type: COMPARATOR
Intervention: Obese men post exercise
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Lean men during exercise
Number of subjects: 16

Group type: COMPARATOR
Intervention: Obese men during exercise
Number of subjects: 16
Study: 30649836

Group type: EXPERIMENTAL
Intervention: 2000 IU day‐1 of vitamin D3
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 30303348

Group type: EXPERIMENTAL
Intervention: Segmental RF ablation (Venefit)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Monopolar RF ablation (EVRF)
Number of subjects: 193
Study: 26553475

Group type: EXPERIMENTAL
Intervention: DUAL tDCS
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: UNI tDCS
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 20
Study: 25311286

Group type: EXPERIMENTAL
Intervention: Resilience Triple P (RTP)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Assessment Control (AC)
Number of subjects: 111
Study: 22357252

Group type: EXPERIMENTAL
Intervention: Paclitaxel (175 mg/m²) plus carboplatin (AUC5) followed by radiation (50.4 Gy) (arm-A)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Simultaneous radiochemotherapy with cisplatin (40 mg/m²/week) (arm-B)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Arm-A (Paclitaxel and carboplatin)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Arm-B (Cisplatin)
Number of subjects: 263
Study: 20693148

Group type: EXPERIMENTAL
Intervention: Prosdex (Web-based PSA decision aid)
Number of subjects: 514

Group type: COMPARATOR
Intervention: Paper version of the text
Number of subjects: 514

Group type: COMPARATOR
Intervention: Control group that completed the questionnaire
Number of subjects: 514

Group type: COMPARATOR
Intervention: Control group that did not complete a questionnaire
Number of subjects: 514
Study: 17397698

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM) plus slow-release morphine
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo plus slow-release morphine
Number of subjects: 65
Study: 18557676

Group type: EXPERIMENTAL
Intervention: 60-minute classroom activity on infant feeding
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 121
Study: 15191155

Group type: EXPERIMENTAL
Intervention: Budesonide 400 microg once daily
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study: 11747767

Group type: EXPERIMENTAL
Intervention: Domestic anastrozole tablet (1 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Imported anastrozole tablet (1 mg)
Number of subjects: 20
Study: 9006702

Group type: EXPERIMENTAL
Intervention: Initial graft tension of 20 N
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Initial graft tension of 40 N
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Initial graft tension of 80 N
Number of subjects: 70
Study: 8422222

Group type: EXPERIMENTAL
Intervention: Alprazolam (mean daily dose of 5.7 mg)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride (175 mg/d)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 3312502

Group type: EXPERIMENTAL
Intervention: Labetalol (100 to 800 mg BID)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Propranolol (40 to 320 mg)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Labetalol + Diuretic
Number of subjects: 153

Group type: COMPARATOR
Intervention: Propranolol + Diuretic
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 153

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 153
Study: 31615501

Group type: EXPERIMENTAL
Intervention: Prophylactic pain management during medical abortion
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Counseling about pain management before the abortion and support during the abortion process
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Pain management strategies discussed in pre-MA counseling
Number of subjects: 42
Study: 27997236

Group type: EXPERIMENTAL
Intervention: Unidirectional intervention (text messages with reproductive health information)
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: Interactive intervention (text-messaging reproductive health quizzes)
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: Unidirectional intervention
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: Interactive intervention
Number of subjects: 756

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 756
Study: 26153271

Group type: EXPERIMENTAL
Intervention: MPCs (rexlemestrocel-L) 0.3 × 10(6)/kg, n = 15
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: MPCs (rexlemestrocel-L) 1.0 × 10(6)/kg, n = 15
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: MPCs (rexlemestrocel-L) 2.0 × 10(6)/kg, n = 15
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo, n = 16
Number of subjects: 45
Study: 24347422

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting by operators with low annual in-trial volume (mean ≤3.2 procedures/y)
Number of subjects: 1546

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting by operators with intermediate annual in-trial volume (3.2-5.6 procedures/y)
Number of subjects: 1546

Group type: COMPARATOR
Intervention: Carotid artery stenting by operators with high annual in-trial volume (>5.6 procedures/y)
Number of subjects: 1546
Study: 21823276

Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Neiguan (PC 6)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Compound Danshen dripping pill (medicine group)
Number of subjects: 40
Study: 19384788

Group type: EXPERIMENTAL
Intervention: Vasospastic subjects
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 17876407

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) on the right forearm to stimulate the extension of the index finger, 24 blocks for group 1 and 36 blocks for group 2.
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (submitted to 24 blocks of stimulation at a null intensity current).
Number of subjects: 45
Study: 15736011

Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Levofloxacin plus rifampicin
Number of subjects: 292

Group type: COMPARATOR
Intervention: Macrolides
Number of subjects: 292
Study: 11986453

Group type: EXPERIMENTAL
Intervention: Zinc syrup
Number of subjects: 1792

Group type: EXPERIMENTAL
Intervention: Zinc syrup and vitamin A
Number of subjects: 1792

Group type: EXPERIMENTAL
Intervention: Zinc syrup (caretaker administered)
Number of subjects: 1792

Group type: COMPARATOR
Intervention: Placebo syrup
Number of subjects: 1792
Study: 9809947

Group type: EXPERIMENTAL
Intervention: Stent
Number of subjects: 116

Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 116
Study: 7666102

Group type: EXPERIMENTAL
Intervention: Dexamethasone plus granisetron (dexamethasone 8 mg IV + granisetron 3 mg IV)
Number of subjects: 428

Group type: COMPARATOR
Intervention: Granisetron alone (3 mg IV)
Number of subjects: 428

Group type: COMPARATOR
Intervention: Dexamethasone alone (8 mg IV)
Number of subjects: 428
Study: 2548660

Group type: EXPERIMENTAL
Intervention: Sodium valproate (600 mg in 3 divided doses p.o.)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 7
Study: 803997

Group type: EXPERIMENTAL
Intervention: Dihydrogenated ergot alkaloids (DEA) (Hydergine)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Papaverine
Number of subjects: 53
Study: 31203240

Group type: EXPERIMENTAL
Intervention: PACE-D web-based intervention
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 25
Study: 28038376

Group type: EXPERIMENTAL
Intervention: Quadriceps and hamstrings lean muscle volumes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intramuscular fat fractions
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Thigh lean muscle mass
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Isometric strength
Number of subjects: 20
Study: 26077235

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel
Number of subjects: 4954

Group type: COMPARATOR
Intervention: Every-3-week paclitaxel
Number of subjects: 4954

Group type: COMPARATOR
Intervention: Every-3-week docetaxel
Number of subjects: 4954

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 4954
Study: 23575450

Group type: EXPERIMENTAL
Intervention: Ulinastatin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (C)
Number of subjects: 80
Study: 22046702

Group type: EXPERIMENTAL
Intervention: Intranasal ketamine (K)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (M)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intranasal midazolam and ketamine combination (MK)
Number of subjects: 45
Study: 19189403

Group type: EXPERIMENTAL
Intervention: Prediagnostic IL-6 levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-6 and BMI interaction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CRP levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-6 genotype
Number of subjects: 0
Study: 16798680

Group type: EXPERIMENTAL
Intervention: Experimental vocational counseling program
Number of subjects: 211

Group type: COMPARATOR
Intervention: Standard vocational counseling program
Number of subjects: 211
Study: 15677433

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional antipsychotics or risperidone
Number of subjects: 0
Study: 11567048

Group type: EXPERIMENTAL
Intervention: TTR fibrils
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cultured neuronal‐like, Schwann, and endothelial cells incubated with TTR fibrils
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: FAP nerves
Number of subjects: 16
Study: 9129016

Group type: EXPERIMENTAL
Intervention: r‐metHuSCF (5, 10, 15, or 20 microg/kg/d) plus Filgrastim (10 microg/kg/d)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Filgrastim (10 microg/kg/d) alone
Number of subjects: 38
Study: 8198905

Group type: EXPERIMENTAL
Intervention: 1.5% lignocaine 15 ml with adrenaline infiltrated into the proposed wound line 3 min before incision
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Lignocaine 15 ml with adrenaline infiltrated into the wound on closure
Number of subjects: 90

Group type: COMPARATOR
Intervention: No wound infiltration
Number of subjects: 90
Study: 3297075

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 0
Study: 31420064

Group type: EXPERIMENTAL
Intervention: Dexamethasone (intramuscular regimen)
Number of subjects: 6018

Group type: COMPARATOR
Intervention: Placebo (identical regimen of normal saline)
Number of subjects: 6018
Study: 24574052

Group type: EXPERIMENTAL
Intervention: Levofloxacin (LFX) 500 mg, once daily (o.d.)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo, once daily (o.d.)
Number of subjects: 65
Study: 23731579

Group type: EXPERIMENTAL
Intervention: Rocker shoe designs with varying apex angle, apex position, and rocker angle
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Rocker shoe designs with varying apex angle
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control shoe (flexible)
Number of subjects: 48
Study: 21383263

Group type: EXPERIMENTAL
Intervention: Combined therapy (cognitive behavior therapy plus switch to a different antidepressant medication)
Number of subjects: 334
Study: 20030546

Group type: EXPERIMENTAL
Intervention: Aerobic exercise for two months
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 35
Study: 16485749

Group type: EXPERIMENTAL
Intervention: Lempel‐Ziv (LZ) complexity
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Approximate entropy (ApEn)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Central tendency measure (CTM)
Number of subjects: 40
Study: 15100917

Group type: EXPERIMENTAL
Intervention: Inpatient rehabilitation (IPR)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Outpatient rehabilitation (OPR)
Number of subjects: 150
Study: 11096167

Group type: EXPERIMENTAL
Intervention: Annual screening
Number of subjects: 46551

Group type: EXPERIMENTAL
Intervention: Biennial screening
Number of subjects: 46551

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 46551
Study: 9574499

Group type: EXPERIMENTAL
Intervention: seven sessions of 1.5 hr each (10.5 hr)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: three sessions of 3.5 hr each (10.5 hr)
Number of subjects: 151

Group type: COMPARATOR
Intervention: no-intervention condition
Number of subjects: 151
Study: 7530706

Group type: EXPERIMENTAL
Intervention: Inhaled substance P (SP) at doses of 0.25-8 mg/ml
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 3414575

Group type: EXPERIMENTAL
Intervention: Citrus extract
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ascorbic acid (AA)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Citrus extract ascorbate
Number of subjects: 20
Study: 30230399

Group type: EXPERIMENTAL
Intervention: Trichuris suis Ova (TSO) 2,500 ova every 2 weeks for 12 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30309257

Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program adapted core weight loss program for 6 months
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: 12-month maintenance treatment
Number of subjects: 426

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Church participation
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: WL participation
Number of subjects: 426
Study: 28618292

Group type: EXPERIMENTAL
Intervention: Anodal tsDCS (2.5mA, 15min)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cathodal tsDCS (2.5mA, 15min)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham tsDCS
Number of subjects: 26
Study: 25650104

Group type: EXPERIMENTAL
Intervention: 1.5-mA anodal tDCS
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 1.5-mA cathodal tDCS
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 15
Study: 24382221

Group type: EXPERIMENTAL
Intervention: Suction drainage
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nondrainage
Number of subjects: 40
Study: 21434488

Group type: EXPERIMENTAL
Intervention: Tramadol/Paracetamol (TP 37.5/325 mg)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Paracetamol/Codeine (CP 30/500 mg)
Number of subjects: 122
Study: 19097715

Group type: EXPERIMENTAL
Intervention: 60 mg raloxifene (RLX)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 0.5 mg percutaneous 17beta-estradiol associated to 60 mg raloxifene (RLX+E2)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 52
Study: 16597042

Group type: EXPERIMENTAL
Intervention: Sleeve circumcision of prepuce and coronary sulcus skin
Number of subjects: 69

Group type: COMPARATOR
Intervention: Electric cauterization of verrucae plus general circumcision
Number of subjects: 69
Study: 12775172

Group type: EXPERIMENTAL
Intervention: Access to the program (treatment group)
Number of subjects: 39

Group type: COMPARATOR
Intervention: No access to program (control group)
Number of subjects: 39
Study: 12529875

Group type: EXPERIMENTAL
Intervention: Maximum likelihood estimation of cumulative probabilities
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional estimator of cumulative success probabilities
Number of subjects: 0
Study: 10990237

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (13 mg/m2 every morning and 3 mg/m2 every afternoon for 12 weeks)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 8649699

Group type: EXPERIMENTAL
Intervention: 200 micrograms of misoprostol
Number of subjects: 80

Group type: COMPARATOR
Intervention: 50 mg of vitamin B6
Number of subjects: 80
Study: 1730840

Group type: EXPERIMENTAL
Intervention: Platelet-activating factor (PAF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Allergen
Number of subjects: 0
Study: 6150997

Group type: EXPERIMENTAL
Intervention: External cephalic version with tocolysis (ECV‐T) attempted
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (no ECV‐T attempted)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Failed ECV‐T
Number of subjects: 88

Group type: COMPARATOR
Intervention: Spontaneous conversion to cephalic presentations
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Complications from ECV‐T
Number of subjects: 88
Study: 3579005

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Orally administered theophylline
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Combination of inhaled salbutamol and orally administered theophylline
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 31962050

Group type: EXPERIMENTAL
Intervention: Cervarix and Gardasil (HPV vaccines)
Number of subjects: 12
Study: 31255678

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 969

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 969

Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 969

Group type: COMPARATOR
Intervention: No treatment (absent depression)
Number of subjects: 969
Study: 30580340

Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg thrice daily
Number of subjects: 72

Group type: COMPARATOR
Intervention: Optimal medical therapy (Control)
Number of subjects: 72
Study: 25952634

Group type: EXPERIMENTAL
Intervention: Insulin glargine plus gliclazide modified release combination therapy
Number of subjects: 105

Group type: COMPARATOR
Intervention: Premixed insulin monotherapy
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 105
Study: 23498848

Group type: EXPERIMENTAL
Intervention: SYN1 (0.8 g/dL Orafti®Synergy1) supplemented infant formula
Number of subjects: 252

Group type: COMPARATOR
Intervention: Control infant formula
Number of subjects: 252
Study: 21256943

Group type: EXPERIMENTAL
Intervention: Nasal sonic jet nebulizer (NJN)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Nasal mesh nebulizer (NMN)
Number of subjects: 7
Study: 19363624

Group type: EXPERIMENTAL
Intervention: Physical performance tests (Villiger test, Oesch test, Biering‐Sørensen test)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group (n = 30)
Number of subjects: 162